logo
Plus   Neg
Share
Email

Airbus: Brexit No Deal Scenario Directly Threatens Airbus' Future In The UK

Airbus (EADSF.PK,EADSY.PK) stated that the UK exiting the EU next year without a deal would lead to severe disruption and interruption of UK production. The company said such a scenario would force Airbus to reconsider its investments in the UK, and its long-term footprint in the country.

Airbus has published a risk assessment outlining the urgent risks to its business arising from the UK exiting the European Union without a withdrawal agreement. The Memorandum stated that while an orderly Brexit with a withdrawal agreement is preferable to a no-deal scenario, the current planned transition (which ends in December 2020) is too short for Airbus to implement the required changes with its extensive supply chain. In such a scenario, Airbus said, it would carefully monitor any new investments in the UK and refrain from extending the UK suppliers/partners base.

Tom Williams, Chief Operating Officer of Airbus Commercial Aircraft, said: "In any scenario, Brexit has severe negative consequences for the UK aerospace industry and Airbus in particular. Therefore, immediate mitigation measures would need to be accelerated. Without these, Airbus believes that the impacts on our UK operations could be significant. Put simply, a No Deal scenario directly threatens Airbus' future in the UK."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT